Catalog No.: PC-35597Not For Human Use, Lab Use Only.
VERU-111 (Sabizabulin, VERU111) is an oral cytoskeleton disruptor that targets and inhibits microtubules to disrupt androgen receptor transport into the nucleus, shows broad antiviral activity by disrupting the intracellular transport of viruses such as SARS CoV-2.
VERU-111 (Sabizabulin, ABI-231) is an oral cytoskeleton disruptor that targets and inhibits microtubules to disrupt androgen receptor transport into the nucleus, shows broad antiviral activity by disrupting the intracellular transport of viruses such as SARS CoV-2.
VERU-111 (Sabizabulin, VERU111) inhibits cell viability of human melanoma cell lines (A375, M14, and RPMI7951) with IC50 of 5-10 nM.
Sabizabulin was tested in a Phase 1b/2 clinical study in men with metastatic castration resistant prostate cancer (mCRPC), as well as COVID-19 infection.
1. Wang Q, et al. J Med Chem. 2018 Aug 30. doi: 10.1021/acs.jmedchem.8b00827.
2. Mark C Markowski, et al. Clin Cancer Res. 2022 Apr 13;clincanres.0162.2022.
